Literature DB >> 20693987

OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.

Pedro P Medina1, Mona Nolde, Frank J Slack.   

Abstract

MicroRNAs (miRNAs) belong to a recently discovered class of small RNA molecules that regulate gene expression at the post-transcriptional level. miRNAs have crucial functions in the development and establishment of cell identity, and aberrant metabolism or expression of miRNAs has been linked to human diseases, including cancer. Components of the miRNA machinery and miRNAs themselves are involved in many cellular processes that are altered in cancer, such as differentiation, proliferation and apoptosis. Some miRNAs, referred to as oncomiRs, show differential expression levels in cancer and are able to affect cellular transformation, carcinogenesis and metastasis, acting either as oncogenes or tumour suppressors. The phenomenon of 'oncogene addiction' reveals that despite the multistep nature of tumorigenesis, targeting of certain single oncogenes can have therapeutic value, and the possibility of oncomiR addiction has been proposed but never demonstrated. MicroRNA-21 (miR-21) is a unique miRNA in that it is overexpressed in most tumour types analysed so far. Despite great interest in miR-21, most of the data implicating it in cancer have been obtained through miRNA profiling and limited in vitro functional assays. To explore the role of miR-21 in cancer in vivo, we used Cre and Tet-off technologies to generate mice conditionally expressing miR-21. Here we show that overexpression of miR-21 leads to a pre-B malignant lymphoid-like phenotype, demonstrating that mir-21 is a genuine oncogene. When miR-21 was inactivated, the tumours regressed completely in a few days, partly as a result of apoptosis. These results demonstrate that tumours can become addicted to oncomiRs and support efforts to treat human cancers through pharmacological inactivation of miRNAs such as miR-21.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20693987     DOI: 10.1038/nature09284

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  30 in total

Review 1.  Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.

Authors:  I Bernard Weinstein; Andrew K Joe
Journal:  Nat Clin Pract Oncol       Date:  2006-08

2.  Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells.

Authors:  B P Zambrowicz; A Imamoto; S Fiering; L A Herzenberg; W G Kerr; P Soriano
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

4.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

5.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

6.  MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor.

Authors:  Jinsong Li; Hongzhang Huang; Lijuan Sun; Mei Yang; Chaobin Pan; Weiliang Chen; Donghui Wu; Zhaoyu Lin; Chunxian Zeng; Yandan Yao; Peter Zhang; Erwei Song
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

7.  Caspase inhibitor ZVAD-fmk facilitates engraftment of donor hematopoietic stem cells in intra-bone marrow-bone marrow transplantation.

Authors:  Yuichiro Imai; Yasushi Adachi; Ming Shi; Chieko Shima; Seiji Yanai; Mitsuhiko Okigaki; Tetsumori Yamashima; Kazunari Kaneko; Susumu Ikehara
Journal:  Stem Cells Dev       Date:  2010-04       Impact factor: 3.272

Review 8.  microRNAs and cancer: an overview.

Authors:  Pedro P Medina; Frank J Slack
Journal:  Cell Cycle       Date:  2008-08-17       Impact factor: 4.534

9.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.

Authors:  Tao Li; Dong Li; Jianjun Sha; Peng Sun; Yiran Huang
Journal:  Biochem Biophys Res Commun       Date:  2009-03-18       Impact factor: 3.575

10.  An ES cell system for rapid, spatial and temporal analysis of gene function in vitro and in vivo.

Authors:  Junhao Mao; Jeffery Barrow; Jill McMahon; Joe Vaughan; Andrew P McMahon
Journal:  Nucleic Acids Res       Date:  2005-10-12       Impact factor: 16.971

View more
  437 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

Review 2.  Developing therapeutic microRNAs for cancer.

Authors:  A G Bader; D Brown; J Stoudemire; P Lammers
Journal:  Gene Ther       Date:  2011-06-02       Impact factor: 5.250

3.  MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells.

Authors:  Yingjie Yu; Shailender S Kanwar; Bhaumik B Patel; Phil-Sun Oh; Jyoti Nautiyal; Fazlul H Sarkar; Adhip P N Majumdar
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

Review 4.  Role of microRNAs in lymphoid biology and disease.

Authors:  Muller Fabbri; Carlo M Croce
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 5.  Non-coding RNAs in human disease.

Authors:  Manel Esteller
Journal:  Nat Rev Genet       Date:  2011-11-18       Impact factor: 53.242

6.  Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.

Authors:  Javeed Iqbal; Yulei Shen; Yanyan Liu; Kai Fu; Elaine S Jaffe; Cuiling Liu; Zhongfeng Liu; Cynthia M Lachel; Karen Deffenbacher; Timothy C Greiner; Julie M Vose; Sharathkumar Bhagavathi; Louis M Staudt; Lisa Rimsza; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Timothy W McKeithan; Wing C Chan
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

7.  MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma.

Authors:  Alexander Baraniskin; Jan Kuhnhenn; Uwe Schlegel; Wolf Schmiegel; Stephan Hahn; Roland Schroers
Journal:  J Neurooncol       Date:  2012-06-23       Impact factor: 4.130

8.  A genome-wide transgenic resource for conditional expression of Drosophila microRNAs.

Authors:  Fernando Bejarano; Diane Bortolamiol-Becet; Qi Dai; Kailiang Sun; Abil Saj; Yu-Ting Chou; David R Raleigh; Kevin Kim; Jian-Quan Ni; Hong Duan; Jr-Shiuan Yang; Tudor A Fulga; David Van Vactor; Norbert Perrimon; Eric C Lai
Journal:  Development       Date:  2012-06-28       Impact factor: 6.868

Review 9.  Serum miRNAs as Biomarkers for the Diagnosis and Prognosis of Thyroid Cancer: A Comprehensive Review of the Literature.

Authors:  Mohammad-Reza Mahmoudian-Sani; Ameneh Mehri-Ghahfarrokhi; Majid Asadi-Samani; Gholam-Reza Mobini
Journal:  Eur Thyroid J       Date:  2017-04-07

10.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.